Based on the corporate philosophy of "Takeda-ism" (Integrity: Fairness, Honesty and Perseverance) developed over its long corporate history of more than 230 years, Takeda conducts activities according to the corporate mission to “strive towards better health for people worldwide through leading innovation in medicine.”

Research Grants 57 show all


$2.9M
2014

$5.2M
2015

$3.2M
2016

$16.5M
2017

$6.7M
2018

Publications 107 show all

  • 10
    Factor Xa Inhibitors
  • 10
    Platelet Membrane Glycoproteins/metabolism
  • 7
    Platelet Glycoprotein GPIIb-IIIa Complex/antagonists & inhibitors
  • 6
    Blood Platelets/physiology
  • 5
    Blood Platelets/metabolism
  • 5
    Peptides/pharmacology
  • 5
    Platelet Aggregation Inhibitors/chemical synthesis
  • 5
    Platelet Aggregation Inhibitors/pharmacology
  • 5
    Platelet Glycoprotein GPIIb-IIIa Complex/metabolism
  • 4
    Thrombin/metabolism

Patents 32,969show all

  • 6,091
    C07D - Heterocyclic compounds
  • 5,823
    A61K - Preparations for medical, dental, or toilet purposes
  • 3,028
    C07K - Peptides
  • 1,283
    C07C - Acyclic or carbocyclic compounds
  • 1,249
    C12N - Microorganisms or enzymes
  • 1,104
    G01N - Investigating or analysing materials by determining their chemical or physical properties
  • 778
    C12P - Fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture
  • 569
    C12Q - Measuring or testing processes involving enzymes, nucleic acids or microorganisms
  • 566
    C07F - Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
  • 458
    C07H - Sugars

Clinical Trials 2,148show all

562Phase 3413Phase 2396N/A344Phase 1146Phase 4100Phase 1/Phase 234Other

Contact Information

Chuo
Japan